Biogen

Youtube Subscribe

Open: 240.0 Close: 234.52 Change: -5.48

How to get informed about Biogen Company Inc Stock quickly using an AI.

Are looking for the most relevant information about Biogen? Investor spend a lot of time searching for information to make investment decisions in Biogen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, BIIB, stock, Buy, version, Eisai, drug, and the most common words in the summary are: biogen, alzheimers, drug, inc, news, stock, best, . One of the sentences in the summary was: Needham analyst Ami Fadia maintained a Buy rating on Biogen.. Other searches related to …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

An injected version of Eisai (4523.T) and Biogen (BIIB) Alzheimers drug Leqembi works as well as the current intravenous version at removing toxic brain plaques. Needham analyst Ami Fadia maintained a Buy rating on Biogen.

Today's News

An injected version of Eisai (4523.T) and Biogen (BIIB) Alzheimers drug Leqembi works as well as the current intravenous version at removing toxic brain plaques. We believe that the safety is actually consistent, Priya Singhal, Biogens head of development, said in an interview. Roche settled patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of rheumatoid arthritis drug Actemra. Roche and its subsidiaries Genentech and Chugai Pharmaceutical (4519.T) jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case. Biogen Inc. (BIIB) stock price, quote & news - stock analysis. Analyst Consensus: Strong Buy Stock Forecasts. Analyst consensus: $330.32 (40.85% upside) Biogen Inc. saw new options begin trading today, for the December 8th expiration. Japan approves Alzheimer treatment Leqembi by Eisai and Biogen. Japan approves Alzheimer treatment Leqembi by Eisai and Biogen. Japan approves Alzheimers treatment. Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment. Needham analyst Ami Fadia maintained a Buy rating on Biogen (BIIB) Needham Reaffirms Their Buy Rating on biogen (BIIB) TipRanks lists the best-performing stocks on the market. Biogen is charging $56,000 per person per year for the drug, with out-of-pocket expenses estimated at up to $11,000 annually. FDA approval of aducanumab was “rife with irregularities,” raising “serious concerns about FDAs lapses in protocol and Biogens disregard of efficacy” Biogen Inc. (BIIB) stock price, quote, news & analysis. Is Biogen stock a Buy, Sell or Hold? Biogen has received a consensus rating of buy. Biogen announces layoffs as focus turns to new products. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, BIIB, stock, Buy, version, Eisai, drug, and the most common words in the summary are: biogen, alzheimers, drug, inc, news, stock, best, . One of the sentences in the summary was: Needham analyst Ami Fadia maintained a Buy rating on Biogen.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #alzheimers #drug #inc #news #stock #best.

Read more →

Youtube Subscribe

---